Article
Rheumatology
Casper Webers, Uta Kiltz, Juergen Braun, Desiree van der Heijde, Annelies Boonen
Summary: Treating active SpA improves depressive symptoms, especially with TNF inhibitors (TNFis) which have a stronger effect mainly due to their impact on disease activity.
Article
Medicine, General & Internal
Francisca Sivera, Victoria Nunez-Monje, Cristina Campos-Fernandez, Isabel Balaguer-Trull, Montserrat Robustillo-Villarino, Marta Aguilar-Zamora, Marta Garijo-Bufort, Juan Miguel Lopez-Gomez, Carolina Pena-Gonzalez, Isabel de la Morena, Diego Bedoya-Sanchis, Liliya Yankova-Komsalova, Arantxa Conesa-Mateos, Anna Martinez-Cristobal, Francisco Javier Navarro-Blasco, Jose Miguel Senabre-Gallego, Juan Jose Alegre-Sancho
Summary: This study provided real-world data on the use, effectiveness, and persistence of secukinumab in the treatment of axial spondyloarthritis. The results showed that secukinumab improved disease activity in patients with axSpA, especially in naive and second-line patients, and had high persistence rates up to 24 months.
FRONTIERS IN MEDICINE
(2023)
Article
Rheumatology
Maxime Dougados, Uta Kiltz, Alan Kivitz, Karel Pavelka, Susanne Rohrer, Suzanne McCreddin, Erhard Quebe-Fehling, Brian Porter, Zsolt Talloczy
Summary: This study demonstrated the long-term NSAID-sparing effect of secukinumab in r-axSpA patients over a 4-year period, showing a consistent reduction in NSAID intake and improvement in ASAS-NSAID score.
RHEUMATOLOGY INTERNATIONAL
(2022)
Article
Immunology
Miladi Saoussen, Makhlouf Yasmine, Nacef Lilia, Fazaa Alia, Bousaa Hiba, Ben Abdelghani Kawther, Laatar Ahmed
Summary: The use of biologics has revolutionized the treatment of axial spondyloarthritis, with gradual tapering strategies showing success in maintaining sustained remission. However, further research is needed to explore the specific implications of each subset and establish more standardized tapering strategies.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2022)
Article
Immunology
Xinzhe Feng, Wenwen Tong, Jia Li, Yihong Xu, Shanbang Zhu, Weidong Xu
Summary: The study found that anti-Kaiso autoantibodies have diagnostic value in the early diagnosis of non-radiographic axial spondyloarthritis (nr-axSpA) and are correlated with clinical disease indicators.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Immunology
Liudan Tu, Churong Lin, Ya Xie, Xiaohong Wang, Qiujing Wei, Yanli Zhang, Jieruo Gu
Summary: This study found that patients with radiographic axial spondyloarthritis (r-axSpA) showed more active inflammatory and chronic structural damages on MRI compared to non-radiographic axial spondyloarthritis (nr-axSpA) patients, especially in terms of fat metaplasia and ankylosis.
FRONTIERS IN IMMUNOLOGY
(2021)
Review
Rheumatology
Victoria Navarro-Compan, Alexandre Sepriano, Bassel El-Zorkany, Desiree van der Heijde
Summary: Axial spondyloarthritis is a chronic inflammatory disease primarily affecting the axial skeleton, leading to symptoms such as chronic back pain and spinal stiffness. Diagnosis relies on recognizing clinical patterns and utilizing clinical, laboratory, and imaging features. Treatment options include non-steroidal anti-inflammatory drugs as first-line therapy, with biologics as a second-line option, showing efficacy in improving disease symptoms.
ANNALS OF THE RHEUMATIC DISEASES
(2021)
Article
Chemistry, Medicinal
He-xiang Zong, Sheng-qian Xu, Jian-xiong Wang, Yi-ran Chu, Ke-ming Chen, Cong Wang, Wan-qiu Tong, Xi-le Wang
Summary: Our study found that imrecoxib showed slight improvement in ASDAScrp within 6 months, while TNFi combined with imrecoxib significantly improved multiple effect indexes in axSpA patients. The efficacy of imrecoxib and celecoxib in the treatment of axSpA is equivalent, and they have similar efficacy when combined with TNFi.
DRUG DESIGN DEVELOPMENT AND THERAPY
(2022)
Review
Rheumatology
Jurgen Braun, Uta Kiltz, Bjorn Buhring, Xenofon Baraliakos
Summary: Axial spondyloarthritis (axSpA) is a chronic inflammatory rheumatic disease characterized by inflammation and new bone formation in the axial skeleton. It is considered one disease with different courses, with two subtypes identified as radiographic and non-radiographic. The pathogenesis is not completely understood, but a strong link with human leukocyte antigen B27 has been identified. Treatment goals focus on controlling symptoms, inflammation, and preventing structural damage.
THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE
(2021)
Article
Rheumatology
Robert D. Inman, Denis Choquette, Majed Khraishi, Dafna D. Gladman, Shamiza Hussein, Drew Neish, Patrick Leclerc
Summary: This study aimed to describe the real-world use of Secukinumab (SEC) in Canadian patients with axSpA. The results showed that SEC was effective in treating axSpA, with improvements in disease activity observed in patients after 12 months of treatment.
JOURNAL OF RHEUMATOLOGY
(2023)
Review
Allergy
Zhi-Bin Zhao, Zhen-Hua Bian, Zhang-Mei Lin, Shu-Fan Wu, Jie Long, Yang Cui, Yang Li, Wende Li, Er-Wei Sun, Zhe-Xiong Lian, Yi He
Summary: Our study characterized the immune landscape of Ax-SpA patients before and after anti-TNF alpha treatment at the single-cell level. We found an increase in peripheral granulocytes and monocytes in Ax-SpA patients, and identified a more functional subtype of regulatory T cells in synovial fluid after treatment. Additionally, we observed a cluster of inflammatory monocyte subset with stronger inflammatory and chemotactic characteristics.
CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY
(2023)
Review
Medicine, General & Internal
Alexandros A. Drosos, Aliki I. Venetsanopoulou, Paraskevi V. Voulgari
Summary: Spondyloarthritis (SpA) is a chronic inflammatory disease that mainly affects the axial skeleton and/or the peripheral joints and entheses. Significant progress has been made in understanding and managing SpA in the past few decades, including early disease recognition, classification, diagnosis, and treatment strategies.
EUROPEAN JOURNAL OF INTERNAL MEDICINE
(2023)
Article
Rheumatology
Nuh Atas, Bagdagul Cakir, Fatih Bakir, Murat Ucar, Hasan Satis, Gizem Tugce Guz, Kubra Durmus Demirel, Hakan Babaoglu, Reyhan Bilici Salman, Aslihan Avanoglu Guler, Hazan Karadeniz, Seminur Haznedarogu, Berna Goker, Mehmet Akif Ozturk, Abdurrahman Tufan
Summary: This study aimed to investigate the impact of anti-TNFs on patients with axSpA and found that many inflammatory cytokines increase after anti-TNF treatment, while noggin levels are not affected.
CLINICAL RHEUMATOLOGY
(2022)
Article
Rheumatology
Sizheng Steven Zhao, Gareth T. Jones, Gary J. Macfarlane, David M. Hughes, Robert J. Moots, Nicola J. Goodson
Summary: The study found that patients with multiple comorbidities in axSpA had poorer treatment outcomes when receiving TNFi therapy, with increased risk of treatment discontinuation, and poorer improvements in function and quality of life.
Review
Medicine, Research & Experimental
Xavier Juanola, Manuel J. Moreno Ramos, Joaquin Maria Belzunegui, Cristina Fernandez-Carballido, Jordi Gratacos
Summary: Axial spondyloarthritis is a chronic inflammatory rheumatic disease that affects the axial skeleton and causes severe pain and disability. Early diagnosis and appropriate treatment can reduce the severity of the disease and the risk of progression. Different types of drugs, such as bDMARDs and JAK inhibitors, are available for treatment. However, treatment failure is common and requires individualized treatment strategies.
ADVANCES IN THERAPY
(2022)
Editorial Material
Rheumatology
Juergen Braun, Xenofon Baraliakos
Review
Rheumatology
Casper Webers, Augusta Ortolan, Alexandre Sepriano, Louise Falzon, Xenofon Baraliakos, Robert B. M. Landewe, Sofia Ramiro, Desiree van der Heijde, Elena Nikiphorou
Summary: This study aims to provide updated evidence on the efficacy and safety of biological disease-modifying antirheumatic drugs (bDMARDs) in patients with axial spondyloarthritis (axSpA) for the revision of management recommendations. The results showed significant efficacy of tumor necrosis factor inhibitors (TNFi) and interleukin-17 inhibitors (IL-17i), while IL-23 inhibitors failed to demonstrate relevant effects. Observational studies are required to confirm the long-term safety of IL-17i.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Editorial Material
Rheumatology
Nelly Ziade, Avin Maroof, Antonella Abi, Torsten Witte, Xenofon Baraliakos
Article
Health Care Sciences & Services
Yu Heng Kwan, Jie Kie Phang, Ting Hui Woon, Jean W. Liew, Maureen Dubreuil, Fabian Proft, Sofia Ramiro, Anna Molto, Victoria Navarro-Compan, Manouk de Hooge, Bhowmik Meghnathi, Nelly Ziade, Sizheng Steven Zhao, Maria Llop, Xenofon Baraliakos, Warren Fong
Summary: The use of social media in health care has various benefits, such as education, information dissemination, telemedicine, research, networking, and communications. This study investigated the motivations, barriers, and patterns of social media use among international experts in spondyloarthritis. The findings showed that most participants use social media for work-related purposes, primarily for professional development, establishing a web-based presence, and international collaboration. Challenges to social media adoption need to be addressed to maximize its benefits.
JOURNAL OF MEDICAL INTERNET RESEARCH
(2023)
Article
Rheumatology
Agnete Overgaard Donskov, Sarah Louise Mackie, Ellen Margrethe Hauge, Carlos Enrique Toro-Gutierrez, Ib Tonder Hansen, Andrea Katharina Hemmig, Aatke Van der Maas, Tamer Gheita, Berit Dalsgaard Nielsen, Karen M. J. Douglas, Richard Conway, Elena Rezus, Bhaskar Dasgupta, Sara Monti, Eric L. Matteson, Sebastian E. Sattui, Mark Matza, Vanessa Ocampo, Margarita Gromova, Rebecca Grainger, Andrea Bran, Simone Appenzeller, Annelise Goecke, Nelly Colman, Helen Keen, Masataka Kuwana, Latika Gupta, Babur Salim, Ghita Harifi, Mariam Erraoui, Nelly Ziade, Nizar Abdulateef Al-Ani, Adeola Ajibade, Johannes Knitza, Line Frolund, Max Yates, Victor R. Pimentel-Quiroz, Andre Marun Lyrio, Maria Sandovici, Kornelis S. M. Van der Geest, Toby Helliwell, Elisabeth Brouwer, Christian Dejaco, Kresten Krarup Keller
Summary: A global survey of general practitioners and rheumatologists revealed that a significant proportion of patients with polymyalgia rheumatica (PMR) are not referred for diagnosis or correctly managed, which has implications for clinical trial recruitment.
Article
Rheumatology
Xenofon Baraliakos, Effie Pournara, Laura C. Coates, Victoria Navarro-Compan, Ricardo Blanco, Eamonn O'Brien, Barbara Schulz, Robert Landewe
Summary: The re-read of baseline spinal MRIs from the MAXIMISE trial revealed that bone marrow oedema, spinal process inflammation, and post-inflammatory changes are common in PsA patients and can predict treatment effects. Post-inflammatory changes were associated with better clinical outcomes, while degenerative changes were associated with worse outcomes.
Article
Medicine, General & Internal
Miriam Frenken, Benedikt Ostendorf, Ralph Brinks, Christoph Schleich, Lena M. Wilms, Stefan Vordenbaeumen, Anja Mueller-Lutz, Jutta G. Richter, Oliver Sander, Gerald Antoch, Matthias Schneider, Xenofon Baraliakos, Daniel B. Abrar, Philipp Sewerin
Summary: This study evaluated the effect of combination therapy with methotrexate and adalimumab versus methotrexate alone on cartilage status in patients with early rheumatoid arthritis using delayed gadolinium-enhanced magnetic resonance imaging of cartilage (dGEMRIC). The results showed that combination therapy resulted in improved cartilage composition, while methotrexate alone did not have any effect on cartilage composition.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Rheumatology
Xenofon Baraliakos, Atul Deodhar, Desiree van der Heijde, Marina Magrey, Walter P. Maksymowych, Tetsuya Tomita, Huji Xu, Ute Massow, Carmen Fleurinck, Alicia M. Ellis, Thomas Vaux, Julie Shepherd-Smith, Alexander Marten, Lianne S. Gensler
Summary: Bimekizumab (BKZ), a monoclonal antibody that inhibits IL-17F and IL-17A, demonstrated sustained efficacy in patients with axial spondyloarthritis (axSpA) at Week 52. The dual inhibition of IL-17A and IL-17F resulted in significant improvements compared to placebo and the safety profile was consistent with previous findings.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Pharmacology & Pharmacy
Volker Kinast, Ioana Andreica, Gerrit Ahrenstorf, Andre Goemer, Carina Elsner, Sarah Schlienkamp, Jil Alexandra Schrader, Mara Klohn, Rainer G. Ulrich, Ruth Broering, Florian W. R. Vondran, Daniel Todt, Patrick Behrendt, Ulf Dittmer, Axel Hamprecht, Torsten Witte, Xenofon Baraliakos, Eike Steinmann
Summary: This study aimed to investigate the influence of JAK inhibitors on HEV replication. The results showed that JAKi treatment increased HEV replication and disrupted the immune response triggered by HEV. Therefore, monitoring potential HEV infections is necessary during JAKi treatment and when liver enzymes are elevated.
ANTIVIRAL RESEARCH
(2023)
Review
Rheumatology
Peter C. Taylor, Ernest Choy, Xenofon Baraliakos, Zoltan Szekanecz, Ricardo M. Xavier, John D. Isaacs, Sander Strengholt, Julie M. Parmentier, Ralph Lippe, Yoshiya Tanaka
Summary: Janus kinases (JAKs) are a family of cytosolic tyrosine kinases that regulate cytokine signal transduction. Several small-molecule JAK inhibitors (JAKis) are now approved for the treatment of immune-mediated inflammatory diseases. Each JAKi has a unique chemical structure, resulting in a distinctive mode of binding and pharmacological characteristics. Differences also exist in selectivity, off-target effects, and various other factors. This review discusses the pharmacological profiles of specific JAKis.
Letter
Rheumatology
Xenofon Baraliakos, Effie Pournara, Laura C. Coates, Victoria Navarro-Compan, Ricardo Blanco, Eamonn O'Brien, Barbara Schulz, Robert Landewe
Article
Rheumatology
R. Naveen, Darpan Thakare, Masataka Kuwana, John Pauling, Jessica Day, Mrudula Joshi, Ioannis Parodis, Parikshit Sen, Kshitij Jagtap, Elena Nikiphorou, Sreoshy Saha, Vishwesh Agarwal, Tulika Chatterjee, James Lilleker, Sinan Kardes, Marcin Milchert, Tamer Gheita, Babur Salim, Tsvetelina Velikova, Abraham Edgar Gracia-Ramos, Ai Lyn Tan, Arvind Nune, Lorenzo Cavagna, Miguel Saavedra, Samuel Katsuyuki Shinjo, Nelly Ziade, Johannes Knitza, Oliver Distler, Hector Chinoy, Rohit Aggarwal, Latika Gupta, Vikas Agarwal, Ashima Makol
Summary: The safety profile of COVID-19 vaccines in patients with systemic sclerosis (SSc) was compared with other rheumatic and non-rheumatic autoimmune diseases, as well as healthy controls. The study found that short-term adverse events following vaccination did not differ significantly between the different groups, and background immunosuppression and disease activity did not influence these events.
RHEUMATOLOGY INTERNATIONAL
(2023)
Review
Medicine, General & Internal
Flinta Rodrigues, Nelly Ziade, Kanon Jatuworapruk, Carlo Caballero-Uribe, Tayyeba Khursheed, Latika Gupta
Summary: This study examines the influence of social media on vaccination attitudes and behaviors in Asia during the pandemic. The findings show that social media, fueled by misinformation and anti-vaccination campaigns, have a detrimental impact on COVID-19 and non-COVID-19 vaccination efforts in Asian countries. However, efforts should be made to leverage social media as a tool to promote informed decision-making and address vaccine hesitancy.
JOURNAL OF KOREAN MEDICAL SCIENCE
(2023)
Article
Rheumatology
Rita Naim, Nelly Ziade, Chafika Haouichat, Fatemah Baron, Sulaiman M. Al-Mayouf, Nizar Abdulateef, Basel Masri, Manal El Rakawi, Lina El Kibbi, Manal Al Mashaleh, Fatemah Abutiban, Ihsane Hmamouchi
Summary: This study estimates the frequency of burnout among rheumatologists in Arab countries and identifies associated factors. The results show a high frequency of burnout among Arab rheumatologists, mainly driven by low personal accomplishment scores. Younger age, dissatisfaction with the specialty, and low income are associated with burnout.
CLINICAL RHEUMATOLOGY
(2023)
Article
Rheumatology
Suhrud Panchawagh, Doskaliuk Bohdana, Masataka Kuwana, Akira Yoshida, Keina Yomono, John D. Pauling, Ashima Makol, Esha Kadam, Jessica Day, Tulika Chatterjee, Wanruchada Katchamart, Phonpen Akarawatcharangura Goo, Elena Nikiphorou, Parikshit Sen, Dzifa Dey, Lorenzo Cavagna, Carlos Enrique Toro Gutierrez, Vishwesh Agarwal, Marcin Milchert, Nelly Ziade, Oliver Distler, C. O. V. A. D. Study COVAD Study Grp, Hector Chinoy, Rohit Aggarwal, Latika Gupta, Vikas Agarwal
Summary: This study analyzed delayed adverse events (ADEs) related to COVID-19 vaccination in patients with systemic sclerosis (SSc) and other systemic autoimmune and inflammatory disorders (SAIDs). The results showed that the risk of delayed ADEs after vaccination was not higher in SSc patients compared to other SAIDs and healthy controls. However, SSc patients with diffuse cutaneous phenotype and coexisting autoimmune conditions such as myositis and thyroid disease may be more prone to experiencing minor ADEs.
RHEUMATOLOGY INTERNATIONAL
(2023)
Review
Rheumatology
Maria Chiara Maccarone, Daniele Coraci, Gianluca Regazzo, Nicola Sarandria, Anna Scanu, Stefano Masiero
Summary: Long COVID syndrome refers to the new, returning, or persistent symptoms after the initial SARS-CoV-2 infection. Musculoskeletal symptoms have a significant impact on the quality of life in many patients. A literature review was conducted to explore the evolution of musculoskeletal symptoms in Long COVID syndrome. The findings highlight the need for interdisciplinary management and timely rehabilitative interventions.
Review
Rheumatology
Alexis Mathian, Renaud Felten, Marta E. Alarcon-Riquelme, Antony Psarras, Philippe Mertz, Francois Chasset, Edward M. Vital, Laurent Arnaud
Summary: Improved understanding of the molecular basis of innate immunity has led to the recognition of type I interferons (IFNs) as key mediators in the development of immunemediated inflammatory diseases (IMIDs). Pharmacological targeting of IFNs and their downstream signaling pathways, such as JAK1 and Tyk2, holds promise for the treatment of IMIDs.
Review
Rheumatology
Marie Robert, Marc Scherlinger
Summary: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by immune dysregulation and organ injury, involving the active role of platelets in the pathogenesis and disease progression. Platelets in SLE patients show intrinsic differences and can perpetuate inflammation by interacting with immune cells, thereby participating in organ damage and heightened cardiovascular mortality.
Review
Rheumatology
Jean Sibilia, Fabrice Berna, Jean-Gerard Bloch, Marc Scherlinger
Summary: Mind-body practices, such as mindfulness meditation, yoga, and Tai Chi, show promise in improving patient-reported outcomes in chronic rheumatic diseases, but their impact on inflammation and structural progression remains unclear.
Review
Rheumatology
Anne Tournadre, Marine Beauger
Summary: Obesity alters the characteristics of adipose tissue, leading to chronic low-grade inflammation, increased risk of chronic inflammatory diseases, and impact on treatment efficacy. Dietary and weight adjustments have a positive effect on improving inflammatory rheumatic diseases.
Article
Rheumatology
Romain Fore, Eric Liozon, Stephanie Dumonteil, Thomas Sene, Emmanuel Heron, Valentin Lacombe, Mathilde Leclercq, Julie Magnant, Clement Beuvon, Alexis Regent, Donatienne de Mornac, Maxime Samson, Perrine Smets, Jean-Francois Alexandra, Brigitte Granel, Pierre-Yves Robert, Muhammad Faiz Curumthaullee, Simon Parreau, Sylvain Palat, Holy Bezanahary, Kim Heang Ly, Anne-Laure Fauchais, Guillaume Gondran
Summary: This study aimed to evaluate whether the use of intravenous pulse of methylprednisolone reduces the risk of bilateral visual ischemia in patients with giant cell arteritis. The results showed no significant difference in the incidence of bilateral visual ischemia between the group receiving intravenous pulse of methylprednisolone and the group receiving direct prednisone.
Review
Rheumatology
Florent Eymard, Judith Aron-Wisnewsky
Summary: Obesity is a major modifiable risk factor for osteoarthritis (OA) and is associated with poorer outcomes in terms of pain, functional limitations, and response to treatments. Bariatric surgery (BS) can significantly reduce symptoms and improve function in patients with symptomatic knee OA, but its impact on long-term complications of arthroplasties appears to be disappointing. Overall, BS shows promise in reducing OA symptoms and potentially slowing disease progression.
Review
Rheumatology
Georges Marouna, Christina Fissouna, Marina Villaverde, Jean-Marc Brondelloa, Yves-Marie Pers
Summary: Recent discoveries have shown that the presence of senescent cells in osteoarticular tissues plays a crucial role in the development of osteoarthritis (OA). However, the senescence-regulatory factors associated with OA still need to be identified. Additionally, there is a lack of diagnostic and prognostic biomarkers currently used in clinics to evaluate OA patients. In the future, detecting senescence-regulatory biomarkers in patient fluids, along with imaging and clinical examination, could become a promising method for diagnosing, monitoring, assessing progression, and predicting prognosis in OA patients.
Article
Rheumatology
Patrick Yousif, Vicky Nahra, Muhammad A. Khan, Marina Magrey
Summary: Axial psoriatic arthritis (axPsA) has unique clinical and radiographic features compared to axial spondyloarthritis (axSpA). IL-23 inhibitors may be effective in treating axPsA, but further clinical trials are needed. Developing classification criteria and assessment tools for axPsA is also necessary.
Review
Rheumatology
Baptiste Gerard, Florian Bailly, Anne-Priscille Trouvin
Summary: This review aims to critically evaluate the effectiveness and safety of pharmacological treatments for chronic pain in rheumatic diseases, providing guidance for clinicians in selecting appropriate treatment options. The recommended pharmacological treatments vary depending on the specific rheumatic disease.